Analogy 1: "Foundation Medicine for functional cancer insights."

• CELx Tests: These are functional diagnostic tests that analyze live tumor cells to identify optimal therapies for cancer patients by measuring drug-induced changes in cell signaling.
• Drug Discovery and Development Services: Celcuity partners with pharmaceutical companies, leveraging its CELx platform to identify novel drug candidates, responsive patient populations, and predictive biomarkers for cancer therapies.

Celcuity (NASDAQ: CELC) primarily operates in a business-to-business (B2B) model, generating revenue through strategic collaborations, licensing agreements, and providing specialized testing services.

Its major customers and collaborators include:

• Pfizer Inc. (NYSE: PFE)
• Bristol-Myers Squibb Company (NYSE: BMY)

Celcuity also provides its CELsignia testing services to various academic institutions and cancer centers for use in clinical studies and investigator-initiated trials, though specific names for these are not typically disclosed as major revenue-generating customers in the same way as its principal pharmaceutical collaborators.

Brian Sullivan, CEO and Co-founder

Brian Sullivan has over 25 years of experience founding and building successful technology companies. He was chairman and CEO of Sterilmed, a medical device company, from 2003 until its sale to Johnson & Johnson for $330 million in 2011. Previously, he was co-founder and CEO of Recovery Engineering, a filtration company that he took public and subsequently sold to Proctor and Gamble for $265 million in 1999. He has received multiple U.S. patents. Sullivan graduated magna cum laude with distinction from Harvard College with an A.B. degree in economics.

Vicky Hahne, CFO

Vicky Hahne has over 20 years of financial leadership experience, including 10 years in the healthcare industry. Prior to joining Celcuity, Hahne served as Controller of Respiratory Technologies Inc., a medical device manufacturer, where she played a key role in the due diligence process to sell the company to Koninklijke Philips. Before Respiratory Technologies, she was Controller for Ability Network Inc., a healthcare information technology company.

Lance Laing, PhD, Chief Science Officer and Co-founder

Lance Laing's career spans more than 30 years in drug discovery research and technology development. He received his doctorate in biophysics and biochemistry from Johns Hopkins University and completed a National Institutes of Health postdoctoral fellowship at Washington University Medical School. He has received multiple U.S. and international patents. His drug discovery research career began at Scriptgen/Anadys Pharmaceuticals (purchased by Novartis). Most recently, he served as an executive director for an international drug discovery and development company. Laing co-founded Celcuity in 2012.

Igor Gorbatchevsky, MD, Chief Medical Officer

Igor Gorbatchevsky is the Chief Medical Officer at Celcuity. Prior to his leadership positions in drug development, he was Professor of Gynecologic Oncology at the University of Iowa, where he led laboratory research focused on identifying genomic variants involved in ovarian cancer. He received his MD from the Baylor College of Medicine, where he also received his PhD in cell biology.

Eldon Mayer, Chief Commercial Officer

Eldon Mayer serves as the Chief Commercial Officer at Celcuity. (No additional background information was readily available from the provided search results.)

Celcuity's primary product, gedatolisib, targets significant addressable markets in oncology.

• For hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer, the projected addressable market potential for a standard of care second-line therapy is approximately $5 billion. This market size is considered global, with estimates suggesting nearly 200,000 late-stage cancer patients worldwide could be eligible for gedatolisib treatment. Some analyses suggest gedatolisib could achieve peak annual sales of $5 billion by 2030, assuming a 30% market share in its initial indication and expansion into first-line settings. Another projection for the second-line breast cancer market alone estimates over $2 billion, assuming a 40% market penetration.
• Beyond breast cancer, early-phase data for gedatolisib in metastatic castration-resistant prostate cancer (mCRPC) and HER2+/PIK3CA-mutated breast cancer show promise, potentially expanding the addressable market to over $10 billion globally over the next decade. Additionally, if the VIKTORIA-2 trial, which evaluates gedatolisib as a first-line treatment in HR+/HER2- advanced breast cancer, is successful, it could unlock a market exceeding $10 billion in earlier lines of care.

Celcuity (NASDAQ: CELC) is a clinical-stage biotechnology company with several anticipated drivers for future revenue growth over the next 2-3 years, primarily centered around its lead therapeutic candidate, gedatolisib, and its diagnostic technology.

1. Regulatory Approval and Commercialization of Gedatolisib in Breast Cancer: The most significant driver of future revenue growth for Celcuity is the potential regulatory approval and subsequent commercialization of gedatolisib for the treatment of HR+/HER2- advanced breast cancer. The company is currently conducting Phase 3 clinical trials, VIKTORIA-1 and VIKTORIA-2, to evaluate gedatolisib in this patient population. Positive outcomes from these trials and subsequent FDA acceptance of a New Drug Application (NDA) are expected to open up a multi-billion dollar market opportunity. Celcuity projects a revenue potential exceeding $2 billion for the second-line breast cancer indication alone, assuming 40% market penetration, with an NDA submission for the PIK3CA wild-type cohort anticipated in Q4 2025.
2. Expansion of Gedatolisib into New Oncology Indications: Beyond breast cancer, Celcuity is also developing gedatolisib for other solid tumor indications, including metastatic castration-resistant prostate cancer (mCRPC). The CELC-G-201 Phase 1b/2 trial for mCRPC has shown promising early data and is continuing to enroll additional patient cohorts. Successful clinical development and regulatory approvals in these additional markets would broaden the addressable patient population and establish new revenue streams. The company identifies a potential addressable patient population of over 500,000 in the US, 5EU, and Japan for cancers involving the PI3K/AKT/mTOR (PAM) pathway, which gedatolisib targets.
3. Growth and Adoption of the CELsignia Diagnostic Platform: Celcuity generates revenue through its diagnostic technology development focused on personalizing cancer treatment. The company's proprietary CELsignia diagnostic platform is designed to identify patients most likely to benefit from targeted cancer therapies by integrating functional profiling of tumor cells with molecular analyses. As a companion diagnostic, wider adoption and increased utilization of this platform, either independently or in conjunction with gedatolisib, could contribute to revenue growth.
4. Strategic Partnerships and Licensing Agreements: Celcuity's existing strategic license agreement with Pfizer Inc. for gedatolisib underscores its capabilities. Future collaborations, expanded partnerships, or additional licensing agreements for gedatolisib or other pipeline assets could generate revenue through upfront payments, milestone achievements, and royalties. The company also actively collaborates with pharmaceutical companies to co-develop new companion diagnostic tests alongside emerging drug candidates, which can streamline clinical development and regulatory approval, thereby generating revenue.

Share Issuance

• In May 2024, Celcuity announced the pricing of an underwritten offering of 3,871,000 shares of its common stock at $15.50 per share, anticipating gross proceeds of $60.0 million.
• In July 2025, Celcuity announced concurrent public offerings totaling $225 million, consisting of $150 million in convertible senior notes due 2031 and $75 million in common stock. The estimated net proceeds from these offerings were approximately $248.7 million.
• Overall, the company raised approximately $287 million through public offerings in July 2025.
• During 2024, Celcuity raised approximately $138.4 million in net proceeds from financing activities.

Inbound Investments

• In May 2024, investors including BVF Partners L.P., Vivo Capital, Eventide Asset Management, Samlyn Capital, Driehaus Capital Management, and Blue Owl Healthcare Opportunities agreed to purchase shares in an offering.
• As of December 31, 2024, institutional investors held approximately 79.37% of Celcuity's shares, with key investors including BVF Inc/Il and Baker Bros. Advisors LP.
• In September 2025, Celcuity amended its senior secured credit facility with Innovatus Capital Partners, LLC and Oxford Finance LLC, increasing the total term loan facility to $500 million, with $350 million in committed capital and an initial funding of $30 million received.

Capital Expenditures

• Celcuity's capital expenditures are primarily focused on research and development (R&D) and clinical trial activities for its lead therapeutic candidate, gedatolisib.
• R&D expenses significantly increased from $60.6 million in 2023 to $104.2 million for the full year 2024. The increase in 2024 was primarily due to costs supporting the VIKTORIA-1 Phase 3 trial, the CELC-G-201 Phase 1b/2 clinical trial, and the commencement of the VIKTORIA-2 Phase 3 trial.
• The company anticipates increasing its R&D expenses for the foreseeable future as it continues to develop gedatolisib, including ongoing and new Phase 3 clinical trials. Celcuity expects its existing cash, cash equivalents, short-term investments, and available borrowings to fund operating and capital expenditure requirements through at least the second half of 2026.